Global Zilbrysq Market

1. Summary

The Global Zilbrysq Market was valued at $220 mn. in 2025. During the forecast period 2025-2030, it is expected to grow at 22.5% CAGR, to an estimated market size of $607 mn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.

2. Market Definition

The market for Zilbrysq (Zilucoplan), a subcutaneous, small-molecule complement C5 inhibitor specifically indicated for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. The scope includes the pharmaceutical sales of the drug across specialty pharmacies, hospitals, and home healthcare settings, excluding other non-C5 inhibitor gMG therapies.

3. Trends & Demand Drivers

Several key trends are expected to significantly impact the Zilbrysq Market in the period 2025-30:

• The transition from hospital-based intravenous (IV) infusions to subcutaneous (SC) self-administration is a primary driver for patient adoption.
• Zilbrysq benefits from a strategic moat as the only once-daily SC complement C5 inhibitor currently available for gMG patients.
• Market growth is heavily influenced by orphan drug designations and priority regulatory reviews that accelerate entry into major global markets.
• High annual drug-acquisition costs, exceeding $450,000 in some regions, necessitate robust reimbursement frameworks and patient support programs.
• Increasing competition from neonatal Fc receptor (FcRn) inhibitors like Vyvgart is forcing a shift toward targeted molecular therapy combinations.
• The expansion of specialty pharmacy networks is facilitating decentralized care and improving long-term patient adherence to therapy.
• Rising prevalence and improved early diagnosis of autoimmune disorders are expanding the eligible patient pool for complement-targeted biologics.

4. Market Breakdown

The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments: